Compare Modine Manufacturing Company (MOD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Organon & Co. Common Stock — how do they compare? Modine Manufacturing Company trades at $156.26 (market cap $9.17B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Modine Manufacturing Company is far larger — about 2.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Organon & Co. Common Stock for 0 Days on average.
| MOD | OGN | |
|---|---|---|
Market Cap | $9.17B | $3.62B |
Volume | 1,397,357 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $283.95 | $13.81 |
52-Week Low | $110.73 | $5.70 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $9.60B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $172.57, showing minimal daily change. The stock exhibits a bearish technical signal with strong selling pressure on moving averages, though oscillators are neutral. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $184 million, but profit margins are expected to compress in 2026. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit with Gentherm, marking a strategic shift.
The outlook is mixed: strong analyst consensus with a $331.25 price target suggests significant upside, but near-term risks include margin pressure and bearish technical trends. Investment opportunity hinges on successful execution post-spin-off and data center cooling growth, while volatility from restructuring and market sentiment poses risks.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
